The microbiome drug developer took its total series C funding to more than $62m, adding $16.6m from investors including Symbiosis, JSR and Bristol-Myers Squibb.
US-headquartered microbiome-based drug developer Vedanta Biosciences has secured $16.6m in series C-2 funding from investors including healthcare services provider Symbiosis, chemicals producer JSR and pharmaceutical firm Bristol-Myers Squibb.
Quad Investment Management, SV Investment Corp, Shinhan Investment-Private Equity, Shinhan Capital-Yeollim Partners, Partners Investment, FC Capital, Bill & Melinda Gates Foundation, Rock Springs Capital, Shumway Capital, Invesco Asset Management and Seventure Partners’ Health for Life fund also invested.
Spun off from pharmaceutical company PureTech Health, Vedanta is developing treatments for immune-mediated diseases…
